1-855-378-42281-855-378-4228
One of the out-patient rehab options for clients in Bomont who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Some clinics and doctors are certified to give specific medications to opioid dependent individuals, many of which are opioid-based also and are addiction. With low amounts however, the user does not experience being high and also doesn't experience acute cravings and is not in opioid withdrawal. Methadone is the first medication tried for this sole purpose, but there are alternative choices currently to select from.
Methadone is an opioid and is meant to be taken at an outpatient medical center licensed to administer the med, which is taken daily in liquid or pill form. The cost of the med is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based drug, and is a pill often taken every other day. But different from Methadone which can only be given in structured medical centers, Buprenorphine can be prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is approximately just under $300 a month for the generic of the medication. There is also a version of buprenorphine containing the drug naloxone, which is a drug that reverses the effects of opiates. An individual taking this version of the drug, AKA Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It is also taken on a daily basis, and costs about $450 /month. Naltrexone is another drug used in opioid maintenance therapy, but unlike the other medications mentioned here it is an opioid blocker and is not an opiate. A person has the choice to take this medication as a monthly shot, and that is called Vivitrol. As an opioid blocker, the drug prevents a person from experience being high from opioids, and therefore lowers the risk associated with relapse. This daily injection costs anywhere from $1000 to $1200 monthly.
For All Drug and Alcohol Rehabilitation Centers In Bomont, Click Here.
